US Markets
SVA

China's Sinovac enters supply deal with Indonesia for COVID-19 vaccine doses

Credit: REUTERS/DIEGO VARA

Sinovac Biotech Ltd said on Tuesday it would help Indonesia's state-owned drugmaker Bio Farma produce in the country at least 40 million doses of its potential coronavirus vaccine before March 2021.

Aug 25 (Reuters) - Sinovac Biotech Ltd SVA.O said on Tuesday it would help Indonesia's state-owned drugmaker Bio Farma produce in the country at least 40 million doses of its potential coronavirus vaccine before March 2021.

The U.S.-listed Chinese drugmaker has signed two agreements with Bio Farma for supply, local production and technology licensing of its vaccine candidate CoronaVac and the Indonesian company is conducting the late-stage study of the candidate.

Sinovac will continue to supply the bulk vaccine until the end of 2021 after March, it said in a statement.

There are no approved vaccine for COVID-19, with drugmakers and research organizations racing to develop a safe and effective vaccine that is seen as crucial to combat the pandemic.

CORRECTED-UPDATE 1-Indonesia books 50 mln coronavirus vaccine doses from Sinovac

FACTBOX- The race for a coronavirus vaccine

FACTBOX-U.S., UK spend billions to take lead in securing coronavirus vaccines

(Reporting by Ankur Banerjee in Bengaluru; Editing by Arun Koyyur)

((ankur.banerjee@thomsonreuters.com;; within U.S. +1 646 223 8780, outside U.S. +91 80 6749 6132; Twitter: @AnkurBanerjee17;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

SVA

Latest Markets Videos

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More